OncoMed Pharmaceuticals said it halted patient enrollment in two early-stage trials for drugs targeting cancer stem cells after observing adverse events related to bones.
from WSJ.com: US Business http://ift.tt/1lpiGVn
via IFTTT
from WSJ.com: US Business http://ift.tt/1lpiGVn
via IFTTT
No comments:
Post a Comment